Meeting
2017 ASCO Annual Meeting
EarlyR genomic signature to predict pathological complete response following neoadjuvant anthracycline-taxane chemotherapy in estrogen-receptor positive (ER+) breast cancer.
Authors
Steven Allen Buechler
University of Notre Dame, Notre Dame, IN
Steven Allen Buechler , Sunil S. Badve , Yesim Gokmen-Polar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Citation
J Clin Oncol 35, 2017 (suppl; abstr 579)
DOI
10.1200/JCO.2017.35.15_suppl.579
Abstract #
579
Poster Bd #
179
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Sperm associated antigen 5 (SPAG5) as a predictor and monitor for response and distant relapse risk (DRR) to endocrine (ET) and chemo-therapies (CT) in oestrogen receptor positive (ER+) breast cancer (BC).
First Author: Tarek Mohamed Ahmed Abdel-Fatah
Poster
2014 ASCO Annual Meeting
INDUCT: A risk score to predict relapse in estrogen-receptor–positive breast cancer.
First Author: Steven Buechler
Poster
2013 ASCO Annual Meeting
Quantitative Ki-67 score as predictive of response to neoadjuvant chemotherapy in breast cancer.
First Author: Jason R. Brown
Poster
2012 ASCO Annual Meeting
Estrogen receptor (ER), Ki-67, p27Kip1, and histologic grade as predictors of pathologic complete response (pCR) in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy (NAC) using fluorouracil, epirubicin, and cyclophosphamide (FEC), taxanes, and trastuzumab.
First Author: Sasagu Kurozumi